Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
US-2017210715-A1 · Jul 27, 2017 · US
PD-1/PD-L1 inhibitors
US10774071B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10774071-B2 |
| Application number | US-201916510647-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 12, 2019 |
| Priority date | Jul 13, 2018 |
| Publication date | Sep 15, 2020 |
| Grant date | Sep 15, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compounds and methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound which is: or a pharmaceutically acceptable salt thereof. 2. A compound which is: or a pharmaceutically acceptable salt thereof. 3. A compound which is: or a pharmaceutically acceptable salt thereof. 4. A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient. 5. The pharmaceutical composition according to claim 4 , further comprising at least one additional anticancer agent selected from rituxan, doxorubicin, gemcitabine, nivolumab, pembrolizumab, atezolizumab, and ipilimumab. 6. The pharmaceutical composition according to claim 5 , wherein the additional anticancer agent is nivolumab, pembrolizumab, atezolizumab, or ipilimumab. 7. A pharmaceutical composition comprising the compound of claim 2 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient. 8. The pharmaceutical composition according to claim 7 , further comprising at least one additional anticancer agent selected from rituxan, doxorubicin, gemcitabine, nivolumab, pembrolizumab, atezolizumab, and ipilimumab. 9. The pharmaceutical composition according to claim 8 , wherein the additional anticancer agent is nivolumab, pembrolizumab, atezolizumab, or ipilimumab. 10. A pharmaceutical composition comprising the compound of claim 3 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient. 11. The pharmaceutical composition according to claim 10 , further comprising at least one additional anticancer agent selected from rituxan, doxorubicin, gemcitabine, nivolumab, pembrolizumab, atezolizumab, and ipilimumab. 12. The pharmaceutical composition according to claim 11 , wherein the additional anticancer agent is nivolumab, pembrolizumab, atezolizumab, or ipilimumab. 13. A method for inhibiting Programmed death-1 (PD-1), Programmed death-ligand 1 (PD-L1) and/or the PD-1/PD-L1 interaction comprising administering the compound of claim 1 or a pharmaceutically acceptable salt thereof, to a patient in need thereof. 14. A method for inhibiting PD-1, PD-L1 and/or the PD-1/PD-L1 interaction comprising administering the compound of claim 2 or a pharmaceutically acceptable salt thereof, to a patient in need thereof. 15. A method for inhibiting PD-1, PD-L1 and/or the PD-1/PD-L1 interaction comprising administering the compound of claim 3 or a pharmaceutically acceptable salt thereof, to a patient in need thereof. 16. A method for treating hepatitis B virus (HBV) comprising administering a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof, to a patient in need thereof. 17. A method for treating hepatitis B virus (HBV) comprising administering a therapeutically effective amount of the compound of claim 2 or a pharmaceutically acceptable salt thereof, to a patient in need thereof. 18. A method for treating hepatitis B virus (HBV) comprising administering a therapeutically effective amount of the compound of claim 3 or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
Assignees
Inventors
Classifications
against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title
specific for leukemia · CPC title
Antineoplastic agents · CPC title
containing further heterocyclic rings · CPC title
- A61K31/444Primary
containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10774071B2 cover?
- Compounds and methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
- Who is the assignee on this patent?
- Gilead Sciences Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/444. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).